The a2 Milk Company Limited (ACOPY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 26.41 means the share price is 26.41 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $3.47B is the value of all shares combined. Beta 0.46: the stock has moved about 54% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerThe a2 Milk Company Limited (ACOPY) trades at $4.78 with MoonshotScore 54/100 (Grade B). Market cap: $3.47B, Sector: Consumer defensive.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ACOPY: ACOPY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACOPY against Consumer Defensive peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ACOPY: 1/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
The a2 Milk Company Limited (ACOPY) Consumer Business Overview
The a2 Milk Company Limited specializes in A2 protein milk and infant formula, differentiating itself through a focus on digestive wellness and operating across Australia, New Zealand, China, and the United States, positioning it within the consumer defensive sector with a focus on health-conscious consumers.
What Is the Investment Thesis for ACOPY?
The a2 Milk Company presents a unique investment proposition centered on its specialized A2 protein milk and infant formula products. With a current P/E ratio of 26.41 and a profit margin of 10.9%, the company demonstrates solid profitability. Key growth catalysts include further expansion in the Chinese market and increased penetration in the U.S. market. The company's strong brand recognition and focus on digestive wellness provide a competitive edge. Potential risks include regulatory changes in the infant formula market and increasing competition from established dairy players. Investors should monitor the company's ability to maintain its premium pricing and manage supply chain complexities. The dividend yield of 1.77% offers a modest return, adding to the investment case.
Based on FMP financials and quantitative analysis
ACOPY Key Highlights
Market capitalization of $3.47B reflects investor confidence in the company's growth prospects.
- Gross margin of 46.8% indicates strong pricing power and efficient cost management.
- Profit margin of 10.9% demonstrates the company's ability to convert revenue into profit.
- Beta of 0.46 suggests lower volatility compared to the overall market.
- Dividend yield of 1.77% provides a steady income stream for investors.
Who Are ACOPY's Competitors?
ACOPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BICEY Société BIC S.A. | $38.52 | +0.82% | $6.38B | 449-signal |
| CHFLF China Feihe Limited | $0.39 | 0.00% | $3.43B | — |
| COCSF Coca-Cola FEMSA, S.A.B. de C.V. | $11.25 | +1.35% | $5.91B | — |
| CUYTY Etn. Fr. Colruyt NV | $11.52 | 0.00% | $5.48B | — |
| GLAPY Glanbia plc | $123.07 | 0.00% | $5.95B | — |
| CALM Cal-Maine Foods, Inc. | $73.71 | +0.66% | $3.46B | 765-pillar |
| BKFKF P/F Bakkafrost | $49.45 | 0.00% | $2.93B | 459-signal |
| KNKZF KWS SAAT SE & Co. KGaA | $84.60 | 0.00% | $2.79B | 579-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ACOPY's Key Strengths?
Strong brand recognition and reputation for quality.
- Focus on a niche market with specific consumer needs.
- Established distribution network in key markets.
- Proprietary knowledge and technology related to A2 protein milk.
What Are ACOPY's Weaknesses?
Reliance on a single product category (A2 protein milk).
- Limited geographic diversification.
- Vulnerability to changes in consumer preferences.
- Potential supply chain disruptions.
What Could Drive ACOPY Stock Higher?
Continued expansion in the Chinese market, driven by high demand for premium infant formula.
- Increased penetration in the U.S. market, targeting health-conscious consumers.
- Potential new product launches, such as A2 protein-based dairy alternatives, in Q3 2026.
- Strategic partnerships with retailers and distributors to expand reach.
- Growing consumer awareness of the benefits of A2 protein milk.
What Are the Key Risks for ACOPY?
Increasing competition from established dairy players in the A2 protein milk market.
- Regulatory changes in the infant formula market, particularly in China.
- Fluctuations in raw material prices, such as milk and packaging materials.
- Changes in consumer preferences and demand for A2 protein milk.
- Currency risk associated with international operations.
What Are the Growth Opportunities for ACOPY?
- Expansion in China: The Chinese market represents a significant growth opportunity for The a2 Milk Company, driven by high demand for premium infant formula and increasing disposable incomes. The company can leverage its brand recognition and distribution network to further penetrate this market. The Chinese infant formula market is estimated to be worth over $25 billion, offering substantial revenue potential. Timeline: Ongoing.
- Increased Penetration in the U.S. Market: The U.S. market offers considerable growth potential for a2 Milk, particularly among health-conscious consumers and those seeking alternatives to traditional dairy products. The company can expand its distribution channels and increase marketing efforts to raise brand awareness. The U.S. dairy alternatives market is projected to reach $45 billion by 2027. Timeline: Ongoing.
- Product Innovation: The a2 Milk Company can drive growth through product innovation, such as developing new A2 protein-based products and expanding its product line to include other dairy-related items. This can attract new customers and increase sales among existing customers. The market for innovative dairy products is growing rapidly, driven by changing consumer preferences. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with retailers and distributors can help The a2 Milk Company expand its reach and increase sales. Collaborating with key players in the dairy and infant formula industries can provide access to new markets and distribution channels. Strategic partnerships can accelerate growth and reduce costs. Timeline: Ongoing.
- Geographic Expansion: The a2 Milk Company can explore opportunities to expand into new geographic markets, such as Southeast Asia and Europe, where there is growing demand for premium dairy products. Entering new markets can diversify revenue streams and reduce reliance on existing markets. The global dairy market is expected to grow at a CAGR of 4% over the next five years. Timeline: Ongoing.
What Are ACOPY's Competitive Advantages?
- Brand recognition and reputation for quality.
- Proprietary knowledge and technology related to A2 protein milk.
- Established distribution network in key markets.
- Focus on a niche market with specific consumer needs.
What Does ACOPY Do?
The a2 Milk Company Limited was founded in 2000 in Auckland, New Zealand, with the aim of commercializing milk products containing only the A2 type of beta-casein protein. The company's core innovation lies in identifying and segregating cows that naturally produce milk without the A1 beta-casein protein, which some studies suggest can cause digestive discomfort in certain individuals. This led to the development of the a2 Milk brand, which is now the company's flagship product. Over the years, a2 Milk has expanded its product line to include infant formula under the a2 Platinum brand, catering to the growing demand for premium infant nutrition. The company has strategically expanded its geographic footprint, establishing a significant presence in Australia and New Zealand, and aggressively targeting the Chinese market, where demand for high-quality infant formula is substantial. It also operates in the United States, focusing on health-conscious consumers. The a2 Milk Company differentiates itself through its focus on A2 protein milk and related products, positioning itself as a premium brand in the consumer defensive sector.
What Products and Services Does ACOPY Offer?
- Sells fresh milk under the a2 Milk brand.
- Offers infant formula under the a2 Platinum brand.
- Focuses on products containing only the A2 type of beta-casein protein.
- Markets its products in Australia, New Zealand, China, and the United States.
- Targets health-conscious consumers and those seeking digestive wellness.
- Differentiates itself through its focus on A2 protein milk.
How Does ACOPY Make Money?
- Produces and sells A2 protein type branded milk.
- Generates revenue from the sale of fresh milk and infant formula.
- Focuses on premium pricing and brand differentiation.
- Utilizes a distribution network to reach consumers in key markets.
What Industry Does ACOPY Operate In?
The a2 Milk Company operates within the agricultural farm products industry, a segment of the broader consumer defensive sector. The industry is characterized by stable demand, as food and beverage products are essential consumer needs. The global dairy market is highly competitive, with major players such as BICEY (Danone), CHFLF (Nestle), COCSF (Fonterra), CUYTY (Unilever), and GLAPY (Lactalis) vying for market share. The a2 Milk Company differentiates itself by focusing on A2 protein milk, catering to consumers seeking digestive wellness. The market for infant formula is particularly lucrative, driven by increasing birth rates in developing countries and growing awareness of premium nutrition.
Who Are ACOPY's Key Customers?
- Health-conscious consumers seeking digestive wellness.
- Parents looking for premium infant formula.
- Retail consumers in Australia, New Zealand, China, and the United States.
- Consumers seeking alternatives to traditional dairy products.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
Why 54?
This rating comes from our nine-signal model, which produces a score but not a per-factor breakdown. The sector-relative five-pillar model, which explains its own contributions, does not cover this listing yet. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 54 |
| 2026-08-26 | 54 |
| 2026-08-29 | 54 |
| 2026-09-01 | 54 |
| 2026-09-04 | 54 |
| 2026-09-07 | 54 |
| 2026-09-10 | 54 |
What changed?
The score has stayed at 54.
Over the same 18 days the stock moved +1.3%.
Company Profile
The a2 Milk Company Limited operates in the Packaged Foods industry within the Consumer Defensive sector. It is headquartered in Auckland, NZ. The company is led by CEO David L. Bortolussi. ACOPY has traded publicly since 2019.
Key Financial Metrics
Return on equity for The a2 Milk Company Limited stands at 15.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.2%, showing how much profit it generates from its asset base. ACOPY trades at a trailing price-to-earnings ratio of 26.41, roughly in line with the Consumer Defensive sector average of ~27.60x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.8%, the inverse of the P/E and a quick read on earnings relative to price.
ACOPY Valuation & Market Position
With a $3.47B market cap, The a2 Milk Company Limited sits in the mid-cap segment of the market. Relative to its peer group, ACOPY's quantitative score of 54/100 is roughly in line with the peer average of 56/100.
Quarterly Financial Performance: The a2 Milk Company Limited
Revenue for The a2 Milk Company Limited came in at $1.01B during Q4 FY2026. The company recorded net income of $105.7M, with diluted EPS of $0.14. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Consumer Defensive. Across the four most recent quarters, ACOPY averaged $0.15 in diluted EPS.
Financial Health
The a2 Milk Company Limited's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.26 places it in the safe zone, indicating low near-term bankruptcy risk.
ACOPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Strong brand recognition and reputation for quality.
- Focus on a niche market with specific consumer needs.
- Established distribution network in key markets.
- Proprietary knowledge and technology related to A2 protein milk.
Bear Case
- Reliance on a single product category (A2 protein milk).
- Limited geographic diversification.
- Vulnerability to changes in consumer preferences.
- Potential supply chain disruptions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2026 | NZ$1.01B | NZ$106M | NZ$0.14 |
| Q2 FY2026 | NZ$1.01B | NZ$115M | NZ$0.16 |
| Q4 FY2025 | NZ$1.01B | NZ$111M | NZ$0.15 |
| Q2 FY2025 | NZ$893M | NZ$92M | NZ$0.13 |
Q4 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Reported in NZD
ACOPY Latest News
-
The a2 Milk Company Limited (ACOPY) Q4 2026 Earnings Call Transcript
seekingalpha.com · Aug 17, 2026
-
Stocks That Managed to Breach 52-Week Highs Wednesday Morning
· Jul 31, 2019
ACOPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ACOPY.
Price Targets
Wall Street price target analysis for ACOPY.
ACOPY MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. ACOPY scores 54/100 (Grade B): the number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Leadership: David L. Bortolussi
CEO
David L. Bortolussi serves as the CEO of The a2 Milk Company Limited, overseeing the company's global operations and strategic direction. His career spans various leadership roles in the consumer goods industry, bringing extensive experience in brand management, marketing, and international expansion. Before joining The a2 Milk Company, Bortolussi held senior positions at prominent multinational corporations, where he led successful product launches and market development initiatives. He is known for his strategic vision and ability to drive growth in competitive markets.
Track Record: Under David L. Bortolussi's leadership, The a2 Milk Company has continued to expand its presence in key markets such as China and the United States. He has focused on strengthening the company's brand recognition and improving its supply chain efficiency. Bortolussi has also overseen the development of new product offerings and the implementation of innovative marketing strategies. His tenure has been marked by a commitment to sustainable growth and shareholder value.
The a2 Milk Company Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For ACOPY, each ADR represents a certain number of shares of The a2 Milk Company Limited traded on its home market. This allows U.S. investors to easily invest in ACOPY without dealing with foreign exchanges.
- Home Market Ticker: New Zealand Stock Exchange (NZX), Auckland, New Zealand
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ACOP
ACOPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher risk of illiquidity and price volatility.
- Lack of regulatory oversight and investor protection.
- Uncertainty regarding the company's financial condition and future prospects.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor and conduct thorough research.
- Understand the risks associated with investing in OTC stocks.
- Established presence in key markets (Australia, New Zealand, China, United States).
- Focus on a niche market with specific consumer needs (A2 protein milk).
- Brand recognition and reputation for quality.
- Continued operations since incorporation in 2000.
- Presence of a CEO and management team.
Common Questions About ACOPY (Consumer Defensive)
What does the AI Score mean for ACOPY?
ACOPY holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. The number comes from the legacy nine-factor engine (quantitative signals from revenue growth to news sentiment), written once, not refreshed.
Is ACOPY a good stock?
Stock Expert AI does not rate ACOPY buy, sell or hold. The a2 Milk Company Limited carries a MoonshotScore of 54/100 on the legacy nine-factor engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does The a2 Milk Company Limited do?
The a2 Milk Company Limited specializes in producing and selling milk and infant formula products that contain only the A2 type of beta-casein protein. The company also offers a2 Platinum infant formula.
What are the key factors to evaluate for ACOPY?
The a2 Milk Company Limited (ACOPY) holds an AI score of 54/100 (moderate). P/E: 26.41x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ACOPY data refresh on this page?
ACOPY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ACOPY's recent stock price performance?
The a2 Milk Company Limited (ACOPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and reputation for quality. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACOPY overvalued or undervalued right now?
The a2 Milk Company Limited (ACOPY) trades at 26.41x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ACOPY?
Yes, most major brokerages offer fractional shares of The a2 Milk Company Limited (ACOPY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ACOPY's earnings and financial reports?
The a2 Milk Company Limited (ACOPY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ACOPY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.